StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Evogene Price Performance
EVGN stock opened at $1.76 on Friday. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40. The firm’s 50-day moving average is $1.69 and its 200 day moving average is $3.21. The company has a market capitalization of $9.44 million, a PE ratio of -0.39 and a beta of 1.30.
Institutional Trading of Evogene
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- Stock Average Calculator
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Roth IRA Calculator: Calculate Your Potential Returns
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Conference Calls and Individual Investors
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
